Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma

被引:17
|
作者
Xu, Lei [1 ]
Wei, Xiu-feng [1 ]
Li, Can-jun [2 ]
Yang, Zhao-yang [3 ]
Yu, Yong-kui [4 ]
Li, Hao-miao [4 ]
Xie, Hou-nai [1 ]
Yang, Ya-fan [1 ]
Jing, Wei-wei [3 ]
Wang, Zhen [1 ]
Kang, Xiao-zheng [1 ]
Zhang, Rui-xiang [1 ]
Qin, Jian-jun [1 ]
Xue, Li-yan [3 ]
Bi, Nan [2 ]
Chen, Xian-kai [1 ]
Li, Yin [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Natl Canc Ctr,Dept Thorac Surg, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Natl Canc Ctr,Dept Radiat Oncol, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Natl Canc Ctr,Dept Pathol, Beijing, Peoples R China
[4] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Thorac Surg, Zhengzhou, Henan, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
neoadjuvant immunotherapy; immunochemotherapy; neoadjuvant chemoradiotherapy; treatment response; postoperative complications; esophageal squamous cell carcinoma; PREOPERATIVE CHEMORADIOTHERAPY; CLINICAL-TRIAL; CHEMOTHERAPY; SAFETY; CANCER; IMMUNOTHERAPY; COMPLICATIONS; CAMRELIZUMAB; FEASIBILITY; EFFICACY;
D O I
10.3389/fimmu.2022.1052542
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundCurrently, the role of immunotherapy in neoadjuvant setting for patients with locally advanced esophageal squamous cell carcinoma (ESCC) is gradually attracting attention. Few studies compared the efficacy of neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT). Our study aimed to compare treatment response and postoperative complications after NICT followed by surgery with that after conventional NCRT in patients with locally advanced ESCC. MethodsOf 468 patients with locally advanced ESCC, 154 received conventional NCRT, whereas 314 received NICT. Treatment response, postoperative complications and mortality between two groups were compared. Pathological response of primary tumor was evaluated using the Mandard tumor regression grade (TRG) scoring system. Pathological complete response (pCR) of metastatic lymph nodes (LNs) was defined as no viable tumor cell within all resected metastatic LNs. According to regression directionality, tumor regression pattern was summarized into four categories: type I, regression toward the lumen; type II, regression toward the invasive front; type III, concentric regression; and type IV, scattered regression. Inverse probability propensity score weighting was performed to minimize the influence of confounding factors. ResultsAfter adjusting for baseline characteristics, the R0 resection rates (90.9% vs. 89.0%, P=0.302) and pCR (ypT0N0) rates (29.8% vs. 34.0%, P=0.167) were comparable between two groups. Patients receiving NCRT showed lower TRG score (P<0.001) and higher major pathological response (MPR) rate (64.7% vs. 53.6%, P=0.001) compared to those receiving NICT. However, NICT brought a higher pCR rate of metastatic LNs than conventional NCRT (53.9% vs. 37.1%, P<0.001). The rates of type I/II/III/IV regression patterns were 44.6%, 6.8%, 11.4% and 37.1% in the NICT group, 16.9%, 8.2%, 18.3% and 56.6% in the NCRT group, indicating a significant difference (P<0.001). Moreover, there were no significant differences in the incidence of total postoperative complications (35.8% vs. 39.9%, P=0.189) and 30-d mortality (0.0% vs. 1.1%, P=0.062). ConclusionFor patients with locally advanced ESCC, NICT showed a R0 resection rate and pCR (ypT0N0) rate comparable to conventional NCRT, without increased incidence of postoperative complications and mortality. Notablely, NICT followed by surgery might bring a promising treatment response of metastatic LNs.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma
    Lv, Huilai
    Zhang, Fan
    Huang, Chao
    Xu, Shi
    Li, Jiachen
    Sun, Bokang
    Gai, Chunyue
    Liu, Zhao
    Wang, Mingbo
    Li, Zhenhua
    Tian, Ziqiang
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (05)
  • [2] Perioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma
    Yang, Xinyu
    Yin, Hao
    Zhang, Shaoyuan
    Jiang, Tian
    Gu, Jianmin
    Jiao, Heng
    Wang, Hao
    Liang, Fei
    Xu, Songtao
    Fan, Hong
    Ding, Jianyong
    Ge, Di
    Wang, Qun
    Yin, Jun
    Tan, Lijie
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2025, 169 (01):
  • [3] Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
    Yu, Yong-kui
    Meng, Fan-Yu
    Wei, Xiu-feng
    Chen, Xian-kai
    Li, Hao-miao
    Liu, Qi
    Li, Can-jun
    Xie, Hou-nai
    Xu, Lei
    Zhang, Rui-xiang
    Xing, Wenqun
    Li, Yin
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 168 (02):
  • [4] A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma
    Tian, Y.
    Shi, Z.
    Wang, C.
    Ke, S.
    Qiu, H.
    Zhao, W.
    Chen, J.
    Gong, Y.
    Wu, Y.
    Zhang, W.
    Xia, L.
    Zhang, Y.
    Chen, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E345 - E345
  • [5] A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma
    Tian, Yuanyuan
    Shi, Zhenguo
    Wang, Chenyu
    Ke, Shaobo
    Qiu, Hu
    Zhao, Wensi
    Wu, Yong
    Chen, Jiamei
    Zhang, Yaowen
    Chen, Yongshun
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : 28 - 30
  • [6] A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma
    Yuanyuan Tian
    Zhenguo Shi
    Chenyu Wang
    Shaobo Ke
    Hu Qiu
    Wensi Zhao
    Yong Wu
    Jiamei Chen
    Yaowen Zhang
    Yongshun Chen
    Annals of Surgical Oncology, 2024, 31 : 860 - 871
  • [7] Neoadjuvant chemo-immunotherapy versus neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
    Wang, X.
    Fang, M.
    Jiang, Y.
    Tao, K.
    Ji, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S165 - S165
  • [8] Neoadjuvant chemoradiotherapy versus chemotherapy and surgery for patients with locally advanced esophageal squamous cell carcinoma
    Hao, Daxuan
    Li, Xue
    Yang, Yuanyuan
    Zhang, Yougai
    Wu, Xiaoyuan
    Chen, Yongshun
    Wang, Jianhua
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 (02) : 346 - 353
  • [9] Neoadjuvant chemoradiotherapy versus chemotherapy and surgery for patients with locally advanced esophageal squamous cell carcinoma
    Hao, Daxuan
    Li, Xue
    Yang, Yuanyuan
    Zhang, Yougai
    Wu, Xiaoyuan
    Chen, Yongshun
    He, Chunyu
    Wang, Wen
    Liu, Jinsong
    Wang, Jianhua
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [10] Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma
    Chen, Fei
    Qiu, Lingdong
    Mu, Yushu
    Sun, Shibin
    Yuan, Yulong
    Shang, Pan
    Ji, Bo
    Wang, Qifei
    FRONTIERS IN SURGERY, 2022, 9